What is RAD-140 (Testolone)?

RAD-140 (Testolone). It is sold for laboratory research use only and is not FDA-approved for human use.

Is RAD-140 (Testolone) FDA-approved or legal to use?

RAD-140 (Testolone) is not FDA-approved for human use and is sold strictly for laboratory research purposes. This page is educational and is not medical advice — consult a licensed healthcare provider before making any health decision.

How strong is the research evidence for RAD-140 (Testolone)?

Evidence varies and much of it comes from preclinical (animal or in-vitro) studies rather than large human trials. Treat reported research dose ranges as study references, not personal-use recommendations, and verify current regulatory status before any research activity.

RAD-140 (Testolone) — Research Literature Summary

⚠ No validated human dose. This compound is not FDA-approved and has no peer-reviewed human dose-finding trials. The figures below are research conventions extrapolated from preclinical (animal/in‑vitro) and community sources — not validated clinical dosing. Treat them as study references only. Research use only; not medical advice.

Class: SARM • Page type: research-literature reference • Updated 2026-04-23

Regulatory notice — research reference only

RAD-140 is an investigational SARM that has not been approved for human use by any regulatory authority. The U.S. FDA and DOJ have explicitly enforced against sale of SARMs for human consumption. This page summarizes published preclinical research only.

Published research summary

RAD-140 (testolone) is a nonsteroidal SARM developed by Radius Health (since discontinued for its original breast cancer indication) with preferential activity at the androgen receptor in muscle and bone.
Preclinical primate studies (Miller et al., ACS Med Chem Lett 2011) reported selective anabolic effects on lean mass with limited androgenic activity at prostate tissue at the doses tested.
Published human data are limited. RAD-140 was investigated in a small oncology trial in AR-positive breast cancer (NCT03088527, terminated); no peer-reviewed safety or efficacy outcomes have been published in its investigational performance context.
Case reports of drug-induced liver injury associated with RAD-140 use have appeared in hepatology literature (e.g., Barbara et al. 2020).
Prohibited at all times on the WADA Prohibited List (S1.2).

Why this page does not publish a consumer “cycle” schedule

No peer-reviewed human efficacy, safety, or dose-finding data support a consumer 'cycle' construct. Published research is preclinical plus one terminated oncology trial.

Peer-reviewed citations

Consulting a healthcare provider: This page is a reference for published research. If you are considering any health decision, consult a licensed healthcare provider. Path to Peptides does not provide medical advice.

⚠ Before any use: human safety data is limited or absent for many of these compounds. Consult a licensed healthcare provider first — especially if you are pregnant or nursing, have a medical condition, or take other medications.